Susquehanna International Group, LLP Infla Rx N.V. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.75 $54,625 - $120,175	-43,700 Reduced 70.71%	18,100 $29,000
Q3 2023 Nov 14, 2023	SELL	$2.66 - $4.33 $147,364 - $239,882	-55,400 Reduced 47.27%	61,800 $184,000
Q2 2023 Aug 11, 2023	BUY	$2.05 - $6.1 $240,259 - $714,920	117,200 New	117,200 $522,000
Q1 2022 May 16, 2022	SELL	$1.83 - $4.48 $465,186 - $1.14 Million	-254,200 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.35 - $5.58 $365,660 - $868,248	155,600 Added 157.81%	254,200 $1.21 Million
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.03 $197,775 - $266,337	87,900 Added 821.5%	98,600 $255,000
Q2 2021 Aug 11, 2021	SELL	$2.72 - $4.04 $100,368 - $149,076	-36,900 Reduced 77.52%	10,700 $32,000
Q4 2020 Feb 16, 2021	SELL	$3.82 - $5.32 $45,840 - $63,840	-12,000 Reduced 20.13%	47,600 $239,000
Q3 2020 Nov 16, 2020	BUY	$3.7 - $5.47 $220,520 - $326,012	59,600 New	59,600 $254,000

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $86.2M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.